MedicineAll countries · Checked
Mounjaro (Tirzepatide): Weight Loss Use, Doses and Price by Country
Mounjaro is a once-weekly tirzepatide injection. As of November 2026 it is licensed for both type 2 diabetes and weight management in the UK and the EU, while in the US Mounjaro is the diabetes brand and the same medicine for weight loss is Zepbound.
Mounjaro at a glance
A once-weekly injection under the skin that acts on both the GIP and GLP-1 hormone receptors.
Medicine and makerTirzepatide, Eli Lilly
Dose range2.5 mg start, 15 mg maximum
How oftenOnce a week
The approved uses differ by country. The sections below sort them out.
Want the exact steps from the first dose?
See the Mounjaro dose chart week by weekThe chart shows the fastest schedule the label allows.
What it isWeight lossDiabetesResultsDoseInjectionSide effectsPriceGenericFAQ
What is Mounjaro (tirzepatide)?
Mounjaro contains tirzepatide. It switches on the receptors for two gut hormones, GIP and GLP-1, which are released after you eat.
You inject it under the skin once a week. The same medicine is sold in the US under a second name, Zepbound.
The US label lists single-dose pens, single-dose vials and a four-dose KwikPen. In India, Lilly launched Mounjaro on 20 March 2025 as a single-dose vial.
Mounjaro for weight loss
In the UK, the MHRA approved Mounjaro for weight management on 8 November 2023. The label criteria are a BMI of 30 or more, or a BMI of 27 to 30 with a weight-related condition such as high blood pressure.
The EU product information uses the same BMI criteria, and so does the Indian approval for chronic weight management. Check your own number with the BMI calculator.
The US is different. Mounjaro is approved for diabetes there, and weight reduction and obstructive sleep apnea are Zepbound's labels. The BMI criteria and doses are the same.
Mounjaro is a prescription medicine, and this page covers only its approved uses.
Mounjaro for type 2 diabetes
Mounjaro was first approved as a diabetes medicine. The US label covers blood sugar control alongside diet and exercise, and lowering the risk of major heart events, such as heart attack and stroke, in adults with type 2 diabetes who are at high risk.
Children and teenagers aged 10 and over can take it for diabetes, with a maximum of 10 mg.
Mounjaro weight loss results
The main trial, SURMOUNT-1, followed adults with obesity or overweight and without diabetes for 72 weeks. The average weight change was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo.
5 mg−15.0%10 mg−19.5%15 mg−20.9%
In SURMOUNT-2, adults with obesity or overweight and type 2 diabetes lost an average of 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo.
These are trial averages, not a promise for any one person. Everyone in the trials also followed a reduced-calorie diet and exercised more.
Mounjaro dose
The starting dose is 2.5 mg once a week for four weeks. The dose then goes to 5 mg and, if needed, up by 2.5 mg after at least four weeks on each step.
Mounjaro doses in brief
Starting dose2.5 mg for 4 weeks
Maintenance doses5, 10 or 15 mg
Maximum dose15 mg once a week
The week-by-week schedule and the missed-dose rules are in the Mounjaro dosing chart.
Mounjaro injection
Take it on the same day each week. Any time of day works, with or without food.
The injection goes into the stomach area, thigh or upper arm, and you change the spot each week. Details are in Mounjaro injection sites.
Keep the medicine in the fridge and never freeze it. Its half-life is about 5 days, which is why one shot a week is enough. See tirzepatide half-life for how long it stays in your body.
Mounjaro side effects
The most common side effects are in the stomach and gut: nausea, diarrhea, vomiting, constipation and stomach pain.
In the US Zepbound label's weight-loss trials, nausea affected 8% on placebo and 25%, 29% and 28% on 5, 10 and 15 mg. Diarrhea affected 8%, 19%, 21% and 23%, and vomiting 2%, 8%, 11% and 13%.
Injection site reactions affected 2% on placebo and 6%, 8% and 8% on 5, 10 and 15 mg.
The US label carries a boxed warning on thyroid C-cell tumors, seen in rats, with no proof either way in people. You cannot use it if you or your family have had medullary thyroid cancer or MEN 2. Your prescriber checks this before the first dose.
Mounjaro price by country
Prices change with the country, the dose and your insurance, so this page does not quote one. Each country has its own page.
Go to the price of Mounjaro in the UK, the US, India, Australia or Canada.
Want every country side by side?
Compare the price of Mounjaro by countryFor coverage, see Mounjaro on the NHS or the PBS.
Generic Mounjaro and similar medicines
Whether a generic tirzepatide exists is answered in Is there a generic Mounjaro?
To compare with semaglutide, read about Wegovy or see every GLP-1 medicine in one place. Approval dates for tirzepatide are in tirzepatide FDA approval.
Mounjaro FAQ
Is Mounjaro approved for weight loss?
Yes in the UK, the EU and India. In the US the weight-loss version is Zepbound, which is the same medicine.
Are Mounjaro and Zepbound the same drug?
Yes. Both are tirzepatide in the same doses, and the name follows the approved use.
How often do you take Mounjaro?
Once a week, on the same day each week.
What is the highest Mounjaro dose?
15 mg once a week. No higher dose is approved.
Can you take Mounjaro without diabetes?
In the UK, the EU and India, adults who meet the BMI criteria can be prescribed it for weight management. Your prescriber decides.
Keep reading
Zepbound (tirzepatide) for weight loss
This page follows official product information and regulator notices and is updated when they change. See how we check our pages.
Update log
: First published.
Sources
Eli Lilly, Mounjaro US prescribing information.
Eli Lilly, Zepbound US prescribing information, including the 72-week Study 1 and Study 2 results.
European Medicines Agency, Mounjaro product information.
MHRA, Mounjaro authorised for weight management.
Eli Lilly India, Mounjaro launch announcement.
GLP1 Note is an independent information site. Which medicine and dose suit you is for your prescriber to decide.